Biospecimen Bone Infection Registry Finds Higher MRSA Rate in North America

An international, biospecimen registry on Staphylococcus aureus in fixation or arthroplasty showed higher rates of MRSA in North American patients and poorer subjective outcomes among those with MRSA vs. methicillin-sensitive S. aureus.

Researchers from the AO trauma Clinical Priority Program (CPP) collected microbiological and immunological data, including bacterial isolates, blood, and sera, from 292 patients with long bone and joint infections.

“Methicillin-resistant S. aureus (MRSA) was detected in 82 patients (28.4%), with the highest proportion found among patients from North American sites (n=39, 48.8%) and the lowest from Central European sites (n=18, 12.2%),” the researchers wrote in the study. “Although patients improved with treatment, less than two-thirds were cured in 1 year. At 12-month follow-up, patient-reported outcome scores were worse for patients with MRSA infections,” they wrote.

 

Click here to read more.

    By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

    The 'OpenSpecimen Biobanking LIMS RFP Q&A' Excel is emailed to you.
    Feel free to Contact Us for any questions.

    Srikanth Adiga,
    C.E.0, OpenSpecimen
    Email: sri@krishagni.com


      Avoid Gmail, Yahoo, etc. please.

      By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

        By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.

        The Features PDF has been emailed to you.
        Feel free to "Schedule a Demo" or "Contact Us" for any questions.

        Srikanth Adiga,
        C.E.0, OpenSpecimen
        Email: sri@krishagni.com

          By submitting to this form, I confirm that I have read and agree to Krishagni's Privacy Policy.